Next, we boosted immunizations with IL-15:IL-15Rα-B16F10-OVA with the same doses 2 weeks after the priming injection to analyze whether the boosting immunization would protect against future exposure to live cancer cell injection in mice (Figure 3A). Here, IL15RA is linked to cancer.